• Sarah Howell, Ph.D., Chief Executive Officer

    Sarah, who joined Arecor in 2011, before being appointed Chief Executive Officer to the Group in 2015, has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas. She has served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had full responsibility for CMC development and supply across BTG’s diverse portfolio of clinical and commercial products.

    Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline. She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee.

    Sarah has an honours degree in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.

  • Susan Lowther, Chief Financial Officer and Company Secretary

    Susan joined Arecor in 2019 as Chief Financial Officer and Company Secretary.  She has significant experience of the life science industry, growing companies and executing M&A transactions.  She also has a strong commercial and operational background, with direct responsibility for finance, HR, IT and facilities functions.

    Susan’s experience as a Chief Financial Officer includes both public and private companies; IXICO plc, Novacyt SA, BioWisdom Ltd and RiboTargets Ltd.

  • Jan Jezek, Ph.D., Chief Scientific Officer

    Jan is a biochemist with a strong background in physical chemistry and the principal inventor of the core protein stabilisation technologies. He is responsible at Arecor for R&D activities, platform development and IP strategy. He played a critical role in the development of stabilising technologies for commercially important therapeutic proteins and vaccines that form the core of Arecor business.

    Previously, he was a Principal Scientist at Insense Limited, a spin-out from Unilever, where he was responsible for the development of novel medical devices, taking them from concept to market.

    Jan holds a joint Doctorate from the University of Bedfordshire and the University of Chemical Technology, Prague. He is a member of the Scientific Advisory Board of the Centre of Excellence in Biopharmaceuticals (University of Manchester) and is an active member of the Formulation Science & Technology Group (FSTG) at the Royal Society of Chemistry and the Biopharmaceutical Group at the Academy of Pharmaceutical Sciences (APS).

  • David Gerring, VP, Development

    David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He is VP, Development at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.

    He has held senior roles at Immunocore and Emergent BioSolutions and his experience includes 5 years at UCB, whilst in a scientific and regulatory capacity. There, he focused on the development and successful licensure of Cimzia. He headed up process and analytical development at BTG, managing CMC for several recombinant products, including successful INDs and licensures.




  • Fiona Lawrence, VP, Clinical & Regulatory Affairs and QA

    Fiona is a pharmaceutical research and development professional and is VP, Clinical & Regulatory Affairs and QA at Arecor, where she has responsibility for driving the clinical development of Arecor’s proprietary products’ portfolio.

    She has broad expertise and experience stemming from work across different organisations in the biotech/pharma, public and not-for-profit/charitable sectors. Previously, she was Director of Research and Clinical Development at Duchenne UK with responsibility for developing the research strategy for the charity. She spent five years at BioMarin and Prosensa in Leiden, working as Senior Clinical Research Manager and four years as Commercial Trials Manager at Cambridge University Hospitals.

    Fiona holds an MSc in Pharmaceutical Medicine from the University of Surrey and a BSc in Pharmacology from the University of Bath.

  • Jim MacDonald-Clink, VP, Business Development

    Jim joined Arecor in November 2019 as VP, Business Development. Jim previously worked at Mundipharma, where he was responsible for Business Development and established the biosimilar platform and oncology strategy via acquisition and licensing agreements. His experience includes acquisition, licensing and strategic partnering initiatives in specialist therapy areas as well as various roles in R&D, Medical and Commercial functions. Jim has over 25 years of experience in healthcare with Mundipharma, Astellas Pharma, Fujisawa, Institute of Cancer Research at the Royal Marsden and Institute of Child Health at Great Ormond Street Hospital, London, UK.

    Jim holds a degree in Medicinal Chemistry.